UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours

British journal of cancer, 2010-06, Vol.103 (1), p.12-17

2010

Volltextzugriff (PDF)

Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice

Annals of oncology, 2001-03, Vol.12 (3), p.405-410

2001

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Cancer chemotherapy and pharmacology, 2011-06, Vol.67 (6), p.1273-1279

2011

Volltextzugriff (PDF)

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ® ): a placebo-controlled randomised phase II study (PLIANT)

Acta oncologica, 2018-01, Vol.57 (3), p.393-402

2018

Volltextzugriff (PDF)

404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.127-127

2008

Volltextzugriff (PDF)

Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis

Thrombosis and haemostasis, 2005-10, Vol.94 (4), p.859

2005

Volltextzugriff (PDF)

Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5519-5519

2008

Volltextzugriff (PDF)

Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16)

Biochemical pharmacology, 1993-08, Vol.46 (3), p.389-393

1993

Volltextzugriff (PDF)

A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.14092-14092

2007

Volltextzugriff (PDF)

A phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3574-3574

2007

Volltextzugriff (PDF)

A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3501-3501

2007

Volltextzugriff (PDF)

A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3137-3137

2005

Volltextzugriff (PDF)

Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study

Blood, 2007-11, Vol.110 (11), p.3453-3453

2007

Volltextzugriff (PDF)

Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells

British journal of cancer, 1990-07, Vol.62 (1), p.37-41

1990

Volltextzugriff (PDF)

Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators

British journal of cancer, 1989-12, Vol.60 (6), p.809-814

1989

Volltextzugriff (PDF)

A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3035-3035

2005

Volltextzugriff (PDF)

181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

European journal of cancer supplements, 2006-11, Vol.4 (12), p.57-57

2006

Volltextzugriff (PDF)

319 POSTER Biochemical characterization of PXD101, a small molecule HDAC inhibitor, and a library of additional compounds on recombinant class I and II HDAC isoforms

European journal of cancer supplements, 2006-11, Vol.4 (12), p.100-100

2006

Volltextzugriff (PDF)

339 Development of HDAC Class I and II specific assays in order to identify novel small molecule inhibitors

European journal of cancer supplements, 2004-09, Vol.2 (8), p.103-103

2004

Volltextzugriff (PDF)

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

European journal of haematology, 2008-09, Vol.81 (3), p.170-176

2008

Volltextzugriff (PDF)

Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins

Biochimica et biophysica acta, 1991-12, Vol.1118 (1), p.83-90

1991

Volltextzugriff (PDF)

Cytosolic free Ca super(2+) in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca super(2+) changes

Biochemical pharmacology, 1991-01, Vol.41 (2), p.243-253

1991

Volltextzugriff (PDF)

In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues

Biochemical pharmacology, 1990-06, Vol.39 (11), p.1721-1726

1990

Volltextzugriff (PDF)

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

Biochemical and biophysical research communications, 2008-03, Vol.367 (4), p.799-804

2008

Volltextzugriff (PDF)

Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cells

Virchows Archiv. B, Cell pathology, 1989, Vol.56 (5), p.327-335

1989

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(60)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours

Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ® ): a placebo-controlled randomised phase II study (PLIANT)

404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors

Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis

Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC)

Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16)

A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors

A phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors

A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors

Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study

Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells

Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators

A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours

181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

319 POSTER Biochemical characterization of PXD101, a small molecule HDAC inhibitor, and a library of additional compounds on recombinant class I and II HDAC isoforms

339 Development of HDAC Class I and II specific assays in order to identify novel small molecule inhibitors

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins

Cytosolic free Ca super(2+) in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca super(2+) changes

In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cells

Suchergebnisse filtern